Formycon AG reports €19.5 million revenue for first nine months of 2025
I'm PortAI, I can summarize articles.
Formycon AG reported revenues of €19.5 million for the first nine months of 2025, down from €41.1 million in 2024, due to a shift from one-time license payments to sales from commercialized products. The company posted an EBITDA of €-21.7 million and a net result of €-21.4 million. Working capital increased to €83.2 million, aided by a €70 million corporate bond. Formycon confirmed its full-year EBITDA guidance and anticipates a positive EBITDA by 2026 or 2027, with key developments in biosimilars in the US and Europe.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments